ClinicalTrials.Veeva

Menu

HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis

N

Naval Military Medical University

Status

Completed

Conditions

Sepsis

Study type

Observational

Funder types

Other

Identifiers

NCT01847248
HSPA12B-sepsis-biomarker

Details and patient eligibility

About

  • Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis.
  • HSPA12B is primarily located in endothelial cells and detectable during sepsis.
  • The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.

Enrollment

118 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adult patients
  • Patients meet the diagnostic criteria according to the grouping

Exclusion criteria

  • patients without informed consent
  • patients who were undergoing continuous renal replacement therapy before sampling
  • patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on

Trial design

118 participants in 4 patient groups

sepsis
Description:
Patients with sepsis but not severe sepsis
Severe sepsis
Description:
Patients with severe sepsis
SIRS
Description:
Patients with SIRS after major orthopedics surgery
Control
Description:
Healthy volunteers

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems